Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Less frequent golimumab dosing with higher doses
NL-OMON21487Recruiting
- Sponsor
- Sint Maartenskliniek
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of golimumab in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA), sponsored by Sint Maartenskliniek. Primary endpoint: Golimumab pharmacokinetic parameters. Started Mar 2020; status: recruiting.
02
Drugs
golimumab
03
Conditions
rheumatoid arthritis (RA)psoriatic arthritis (PsA)axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on NL-OMON21487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21487.